What Entamizole Plus Treats: Main Uses and Benefits

This medicine is commonly used to treat gastrointestinal infections caused by single-celled parasites, specifically applied across domains involving conditions like Amoebiasis and Giardiasis. The medication is applied in conditions presenting with systemic or localized discomfort caused by parasitic forms. It helps address symptom clusters that may appear suddenly, such as severe diarrhea, painful abdominal cramping, and the presence of loose or bloody stools, offering symptomatic relief that helps patients cope more steadily with these distressing episodes.

Key Therapeutic Contexts and Benefits

Entamizole Plus is relevant in clinical settings that involve acute or unstable symptom patterns, requiring the management of parasitic forms across multiple sites. The approach supports symptomatic relief from active infection and is commonly used in situations involving recurrent or episodic manifestations caused by dormant forms. Its therapeutic scope generally extends to other anaerobic infections and protozoal conditions outside the gut, including certain infections in the genitourinary system like Trichomoniasis and the management of extra-intestinal manifestations, such as an amoebic liver abscess.

“The medication is applied in scenarios where additional management of discomfort is required, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Therapeutic Focus on Acute Gastrointestinal Distress This medicine is commonly used in settings marked by temporary physiological imbalance during periods of heightened symptoms, assisting with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

1. NIH StatPearls overview of Entamoeba histolytica infection

Eligibility Map: Who Can and Cannot Use Entamizole Plus — Official Regulatory Information

Eligibility Scope

Category	Status	Details
Allowed Populations	Permitted	Adults and older adults.
Contraindicated Groups	Prohibited	Hypersensitivity to Ornidazole, Diloxanide Furoate, or other nitroimidazole derivatives.
CNS Conditions	Prohibited	Organic Central Nervous System (CNS) diseases, including epilepsy.
Reproductive Status	Contraindicated	Pregnancy and lactation (breastfeeding).
Pediatric Restriction	Not Suitable	Children weighing less than 25 kilograms.
Conditional Use	Restricted	Patients with severe hepatic impairment (dose adjustment required) and those undergoing hemodialysis.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

• Absolute Contraindication: Applies to known hypersensitivity, pregnancy, lactation, and certain CNS disorders.
• Conditional Use/Caution: Applies to severe hepatic impairment and renal impairment during hemodialysis.
• Unsuitable for Use: Applies to the pediatric population below a specified weight threshold.

Resulting Eligibility Structure

Official eligibility statements:

• Contraindicated in patients with a history of hypersensitivity to the active components or related nitroimidazole derivatives.
• Contraindicated during pregnancy and lactation.
• Use is not suitable for children weighing less than 25 kilograms.
• Use is restricted in patients with severe hepatic impairment and conditions affecting the CNS.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documentation defines eligibility by establishing absolute contraindications for hypersensitivity, pregnancy, and lactation. Eligibility is further structured by conditional use requirements for patients with specific comorbidities, such as severe liver impairment, and by setting a minimum weight threshold that limits use in the pediatric population. These rules strictly define the permitted population.

Entamizole Plus is a fixed-dose combination whose interaction profile is strictly derived from the Ornidazole component, as regulatory sources document that Diloxanide Furoate has no known drug interactions. Official regulatory information outlines specific substance restrictions and both pharmacokinetic (PK) and pharmacodynamic (PD) interaction patterns.

The most stringent restriction is a mandatory timing rule for alcohol, which must be strictly avoided during the entire course of therapy and for a minimum of 3 days after discontinuing the medicine. Furthermore, co-administration with Disulfiram is classified as a high-risk combination due to the potential for acute confusion and psychosis.

Documented Interactions

• Exposure-Altering: Ornidazole may potentiate the anticoagulant effect of coumarin-type medicines (e.g., Warfarin). Lithium plasma levels may also be increased. The clearance of 5-fluorouracil may be reduced, carrying a documented risk of toxicity.
• Metabolic: Cimetidine may decrease Ornidazole clearance, potentially prolonging its half-life. Conversely, Phenobarbital and Phenytoin may reduce the half-life of Ornidazole.
• Pharmacodynamic: The muscle relaxant effect of Vecuronium bromide is documented to be prolonged.

Regulatory documents specify that there are no clinically relevant interactions documented between the medicine and food.

How Entamizole Plus Works: Dual-Compartment Eradication

The mechanism of Entamizole Plus is defined by the anatomical complementarity of its two active ingredients, contributing to the comprehensive targeting of the parasite at both the tissue and luminal level.

---

Systemic DNA Fragmentation (Ornidazole)

This mechanistic domain is centered on the bioactivation of Ornidazole by the parasite's low-oxygen metabolism. The drug is transformed into toxic free radical species that covalently bind to and destroy the parasite's DNA. This action leads to the systemic elimination of the organisms that have invaded the body's tissues (extraluminal forms), leading to the reduced presence of tissue-invasive forms.

---

Targeted Luminal Cytotoxicity (Diloxanide Furoate)

This domain achieves the destruction of the parasite's source of infection within the gastrointestinal tract. Diloxanide Furoate is activated in the gut, where it exerts a direct amoebicidal effect, primarily by inhibiting protein synthesis in the active trophozoites and the resistant cysts. This localized action results in the clearance of the intestinal reservoir, which functionally limits the persistence of the organism and its potential for systemic movement.

The administration of this fixed-dose combination (FDC) drug is structured around strict oral intake rules and component-specific dose requirements. The usage protocol dictates the standardized steps for proper use.

General Administration

This medicine is administered via the oral route as a tablet and must be swallowed whole with water. Instructions dictate that the tablet must be taken with food or after meals to support proper intake and minimize gastrointestinal irritation. Compliance with the full prescribed time course is required; if a dose is missed, individuals should not take a double dose to compensate.

Dosage and Course Duration

The total dose is determined by combining the labeled dose ranges for the Ornidazole and Diloxanide Furoate components.

Component	Standard Adult Regimen	Course Duration
Diloxanide Furoate	500 mg three times daily (TID)	Typically ten days
Ornidazole	1000 mg to 2000 mg daily in divided doses	Varies between three and ten days

Population-Specific Use

For pediatric patients, dosing is based on body weight, with the Diloxanide Furoate component typically dosed at 20 mg/kg body weight daily in divided doses; the component is generally not suitable for children weighing less than 25 kg. Special procedural conditions apply to the Ornidazole component in cases of severe impairment: dose adjustment may be required for severe hepatic impairment, and a supplemental dose must be administered on days of haemodialysis. This use protocol defines the required frequency and the time-limited nature of the treatment.

Research Evidence / Overview of Studies for Entamizole Plus

This section provides an overview of the research base for Entamizole Plus, a fixed-dose combination (FDC) of Ornidazole and Diloxanide Furoate, drawing on clinical trials, systematic reviews, and official documentation. This summary is intended to be purely descriptive and contains no medical advice or treatment recommendations.

---

Evidence for Use in Intestinal Amoebiasis

Clinical research for intestinal amoebiasis has explored the role of agents that act in both the body’s tissues and the gut lumen. Randomized Controlled Trials (RCTs) have studied this class of antiprotozoal drugs, often including the FDC’s component agents as a comparator against other treatments. Researchers typically focused on two main study outcomes: the parasitological outcome (clearance of the amoeba forms from stool specimens) and the clinical outcome (evaluation of outcomes related to physical discomfort, such as severe diarrhea).

Some trials reported that the use of the combined systemic and luminal agents was studied for its role in investigating parasite clearance from both the tissue and the gut. Studies monitoring the FDC described patterns of how symptoms evolved in the observed populations within the short-term follow-up period. Research highlights that long-term outcomes are not fully established regarding the durability of parasite clearance beyond the first month post-treatment.

Evidence for Use in Giardiasis

The research base for Giardiasis primarily has studied the nitroimidazole class of drugs, to which Ornidazole belongs. Research examined the use of these agents in RCTs, often including them as a comparator against other protozoal treatments. Study outcomes focused on the achievement of parasitological outcome (eradication of Giardia lamblia forms) and the documentation of clinical symptom resolution. Studies focusing on Ornidazole reported outcomes consistent with its recognized role as a systemic agent for Giardiasis. However, the specific contribution of Diloxanide Furoate to the Giardiasis outcomes within the FDC is less characterized.

What Remains Uncertain in the Research

Evidence quality varies across studies, and many older trials complicate certainty due to differences in diagnostic accuracy and outcome definitions. The specific FDC of Ornidazole and Diloxanide Furoate is less studied in major, high-tier meta-analyses, and certain comparative evidence is lacking. Limited information for long-term outcomes means that the data for long-term stability over many months or years are not consistently established across the research base.

Key Studies & References

1. NIH StatPearls: Entamoeba histolytica Infection
2. WHO Model Lists of Essential Medicines (Antiprotozoal Medicines Section)
3. PubChem: A public repository for chemical structures and bioactivities (National Library of Medicine)
4. DrugBank Online: Database for Drug and Drug Target Information

Common questions about Entamizole Plus (FAQ)

---

Q: Can taking this medicine cause fatigue or unusual tiredness?

Official product information, based on the data for one of the active components (Ornidazole), states that fatigue or unusual tiredness is listed as a possible adverse effect. Regulatory documents classify this effect as very rare. Individuals experiencing unexpected or severe tiredness are typically advised to consult with a healthcare professional regarding their condition.

---

Q: How quickly will I feel better after starting the treatment (onset of action)?

According to official regulatory documentation, the time taken for the medicine to demonstrate its therapeutic effect, or the onset of action, can vary. This variability is often dependent on factors such as the specific type of infection being addressed and the way the medicine is processed by the body. Research evidence includes monitoring clinical outcomes, such as how symptoms evolve within observed populations.

How to Store and Dispose of Entamizole Plus?

This section explains the mandatory storage and disposal rules for this prescription oral tablet, as defined by official regulatory labeling.

Storage Requirement	Official Regulatory Statement
Temperature & Environment	Store below 30 C in a cool and dry place, protecting the tablets from light and excessive heat.
Packaging	The tablets must be kept in the original container or pack, ensuring it remains closed to prevent degradation.
Child Safety	It is mandatory to keep this medicine out of the sight and reach of children and pets.
Disposal	Unused or expired medication must be disposed of in accordance with local regulations or via a drug take-back program. The tablets should not be flushed down the toilet or sink.

Adherence to these official constraints ensures the stability of the medicine, which is necessary for maintaining its quality until the expiration date, while following disposal rules protects public safety and the environment.